稳定肾移植患者他克莫司全血与外周血单核细胞浓度的群体药代动力学
该前瞻性研究纳入63例稳定成人肾移植患者,采集他克莫司全血和PBMC浓度并构建群体药代动力学模型。结果发现PBMC浓度无法由全血浓度和协变量准确预测,CYP3A5*1非表达者和NR1I2-25 385T等位基因表达者的全血与PBMC浓度比值(RC:PBMC)分别高42.4%和60.7%。
要点
- 他克莫司PBMC浓度不能由全血浓度准确预测,需直接测定。
- CYP3A5*1非表达者RC:PBMC比值高42.4%。
- NR1I2-25 385T等位基因表达者RC:PBMC比值高60.7%。
核心结论
- 由于他克莫司向PBMC分布的残余变异显著,PBMC浓度无法由全血浓度和协变量准确预测,未来研究如需PBMC浓度应直接测定。
研究设计与样本
- 前瞻性纳入63例稳定成人肾移植患者,采集密集(12小时,n=18)或稀疏(4小时,n=45)药代动力学 profiles。
- PBMC经Ficoll密度梯度离心从全血分离,全血和PBMC药物浓度采用液相色谱-质谱联用分析。
- 患者CYP3A4/5、ABCB1、NR1I2基因型采用PCR评估,群体药代动力学建模和统计评价使用NONMEM进行。
主要发现
- 他克莫司全血浓度用带滞后时间及一级吸收和消除的二室药代动力学模型可良好描述。
- 他克莫司PBMC浓度最好通过全血浓度乘以缩放因子(全血与PBMC浓度比值RC:PBMC)来估计,该比值反映他克莫司分布进入PBMC的程度。
- CYP3A5*1非表达者和NR1I2-25 385T等位基因表达者的RC:PBMC比值分别高42.4%和60.7%。
临床怎么用
- 他克莫司常规治疗药物监测基于全血浓度,但PBMC浓度不能由全血浓度准确推算,如需评估靶部位暴露应直接测定PBMC浓度。
- CYP3A5*1非表达者和NR1I2-25 385T等位基因表达者的全血与PBMC浓度比值较高,解读PBMC浓度时需考虑基因型影响。
局限性
- 研究纳入稳定成人肾移植患者,结论可能不适用于其他人群或非稳定期患者。
- PBMC浓度分布存在显著残余变异,模型预测准确性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Therapeutic drug monitoring of tacrolimus based on whole blood drug concentrations is routinely performed. The concentration of tacrolimus in peripheral blood mononuclear cells (PMBCs) is likely to better reflect drug exposure at the treatment target site. We aimed to describe the relationship between tacrolimus whole blood and PBMC concentrations, and the influence of patient characteristics on this relationship by developing a population pharmacokinetic model. METHODS: We prospectively enrolled 63 stable adult kidney-transplanted patients and collected dense (12-h, n = 18) or sparse (4-h, n = 45) pharmacokinetic profiles of tacrolimus. PBMCs were isolated from whole blood (Ficoll density gradient centrifugation), and drug concentrations in whole blood and PBMCs were analysed using liquid chromatography-mass spectrometry. Patient genotype (CYP3A4/5, ABCB1, NR1I2) was assessed with PCR. Population pharmacokinetic modelling and statistical evaluation was performed using NONMEM. RESULTS: Tacrolimus whole blood concentrations were well described using a two-compartment pharmacokinetic model with a lag-time and first-order absorption and elimination. Tacrolimus PBMC concentrations were best estimated from whole blood concentrations with the use of a scaling factor, the ratio of whole blood to PBMC concentrations (RC:PBMC), which was the extent of tacrolimus distribution into PBMC. CYP3A5*1 non-expressors and NR1I2-25 385T allele expressors demonstrated higher RC:PBMC ratios of 42.4% and 60.7%, respectively. CONCLUSION: Tacrolimus PBMC concentration could not be accurately predicted from whole blood concentrations and covariates because of significant residual unexplained variability in the distribution of tacrolimus into PBMCs and may need to be measured directly if required for future studies.
引用
- Agergaard K, Thiesson HC, Carstens J, et al. Population pharmacokinetics of tacrolimus whole blood and peripheral blood mononuclear cell concentrations in stable kidney-transplanted patients. Br J Clin Pharmacol. 2024. PMID: 39390741. doi:10.1111/bcp.16277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。